ppt materi om 2 cardiovascular disease
TRANSCRIPT
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
1/44
CARDIOVASCULA
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
2/44
Cardiovascular syste
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
3/44
Hypertension
Coronary Heart Disease
Acute Coronary Syndromes
Valvular Heart Disease
Heart Failures
Arrhythmia
Endocarditis
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
4/44
1 HYERTENSIONDEFINITION• Hypertension is defined as having systolic blood pressure (SBP) >140 m
diastolic blood pressure (DBP) > 90 mmHg• As having to use antihypertensive medications
CLASSIFICATION(According to etiology)
• Primary (Essential)
• Secondary
(According to SBP and DBP score)
• Normal
• Prehypertension
• Stage 1 hypertension
• Stage 2 hypertension
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
5/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
6/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
7/44
RISK FACTORS
• HTN is well recognized risk factors for CAD• With improved control of BP, there has been a
steady decrease in mortality from CHD aneven greater decrease in mortality from stroke
• Treatment focuses on prevention to reducecomplications -> brain, heart, kidney, eyes,
peripheral arteries• Complications -> Cerebral hemorrage, left
ventricular hypertrophy, CHF, renalinsufficiency, etc
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
8/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
9/44
DIAGNOSIS
• Hypertention usually has a long and asymtomatic course -> undiagnosed• Diagnosis is made only after an elevated BP has been recorded on multiple
Stage 1 : SBP 140 to 150 mmHg or DBP 90 to 99 mmHgStage 2 : SBP >160 mmHg or DBP > 100mmHg
• The BP level determines severity of HTN• 3 main goals of medical evaluation :
- Identify tretable of curable cause- Assess the impact of persistently elevated BP on target organs- Estimate the patient overall risk profile for the development of the CVD- Routine history and physical examintaion should be performed
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
10/44
EXAMINATION:
• Routine HistoryDuration of the hypertention and any prior treatment
• Physical Examination -> Sign of end-organ damage and a cause of hypertention and a cause of secondary hypertention, Peripheral puauscultated, funduscopic assessment
• Laboratory Routine blood chemistries, fasting lipid (total, HDL, chotriglycerides), twelve-lead electrocardiography (ECG).
• Additional Testing Electrocardiograhy, Ambulatory BP Monitoring, activity testing, radiologic testing
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
11/44
MANAGEMENT
Lifestyle modification
Medication• Diuretics : Reduce blood volume oral dryness, lichenoid reactio
• b-blockers : reduce stimulation by sympathetic nervous system dryness, oral ulceration, taste changes
• Calcium channel blockers : reduce calcium flow into heart musctherefore heart rate relax smooth muscle lining coronary arteries gingival overgrowth
• Angiotensin-converting enzyme
• Inhibitors (ACEIs) : interfere with renin-angiotensin pathway
• angiotensin II receptor blockers lichenoid reaction
• Direct vasodilators : open up blood vessels (reduce resistance)lupuslike oral and skin lesion, lymphadenophaty
• Centrally acting agents.
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
12/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
13/44
ORAL HEALTH CONSIDERATIONS
• Effect of HTN on Oral Health1. More sensitive to adrenaline in dental anesthetics2. Medications lead to dry mouth3. Increased bleeding after dental surgery
• Dentist should be aware of medications that1. May have systemic side effects that are of importance to provision of care
2. Interact with medications used during dental care3. Cause intraoral changes -> oral dryness, gingival overgrowth, ulceratotions
• Concentrations of epinephrine greater than 1:100.000 aren unnecessary and crisk
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
14/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
15/44
2 CORONARY ARTERY DISEASE (CADDEFINITION• Condition when coronary arteries become narrowed by a gradual b
fatty material within their walls. The condition is called Atherosclerosifatty material is called atheroma
• 30-50% of all CVD
Disrupt of vascularnedothelium
Plaque formation
Chronic reductiocoronary blood floensuing myocar
ischemia/ acute prupture
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
16/44
• Atherosclerosis may affect any vascular bed -> coronary, cerebral. Rmesenteric, and peripheral vascular system
• When end-organ blood flow is compromised, the resulting ischemia subsequent organ dysfunction
ETIOLOGY- Artherosclerosis- Fatty streak -> progress into plaque -> thrombotic occlusions and co
events- Lipid metabolism abnormalities, systemic hypertension, diabetes me
cigarette smoking -> total atherosclerosis plaque burden
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
17/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
18/44
RISK FACTORS- Risk factors assessment is useful as a guide to therapy for dyslipidemia
hypertension, and diabetes
Hypertension DMCigaretteSmoking
LifestyleDiatery f
Exercise Obesity LipidsVitamin
Homocy
PlasmaFibrinogen
AntioxidantsEndothelialDysfunction
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
19/44
RISK FACTORS MODIFICATION- When artherosclerosis is identified -> relieve symptoms and improve o
perfusion
- Risk factor modification -> prevent ongoing atherosclerosis- Smoking cessation, meticulous control of hypertension and DM, weig
management, agressive lipid-lowering therapy -> should be all advise- Lipid-lowering therapy with HMG CoA reductase inhibitor -> reduce m- Low-fat, low-calorie diet -> also effective
DIAGNOSIS
- Clinical presentation -> taking history or resting symptoms including chtightness, jaw discomfort, left arm pain, dyspnea, or epigastric distress
- Test : Blood test, doppler ultrasound, ankle-brachial index, electrocard(ECG). Stress test
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
20/44
MANAGEMENT- High blood pressure -> Angiotensin-converting enzyme (ACE) inhibitors, calci
blockers, thiazide diuretics- High colesterol level -> Statins- Preventing blood clots -> Antiplatelets- Surgery -> Coronary artery bypass graft (CABG), Carotid arteries, Carotid
endarterectomy, carotid angioplasty Extracranial to intracranial bypass
DENTAL CONSIDERATION- Prevent ischemia and infarction
- Impaired hemostatis due to one or more medications may also require dentamodifications
- Side effects from cardiac drugs -> cause oral change- Current cardiac status and medications should be discussed with the patient
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
21/44
3 Acute coronary syndrome
• Sudden rupture of an atherosclerotic plaque with ensuing intracoronathrombus formation that acutely reduces coronary blood flow -> ACUCORONARY SYNDROMES (ACSs)
• Acute coronary syndrome (ACS) refers to a spectrum of clinical presen
ranging from those for ST-segment elevation myocardial infarction (ST
presentations found in non –ST-segment elevation myocardial infarctio
(NSTEMI) or in unstable angina
• Atherosclerosis is the primary cause of ACS
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
22/44
SIGN AND SYMPTOMS
Atherosclerosis is the primary cause of ACS
• Palpitations
• Pain, which is usually described as pressure, squeezing, or a burning
across the precordium and may radiate to the neck, shoulder, jaw, ba
abdomen, or either arm
•
Exertional dyspnea that resolves with pain or rest• Diaphoresis from sympathetic discharge
• Nausea from vagal stimulation
• Decreased exercise tolerance
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
23/44
DIAGNOSIS
Patient’s history, electrocardiography (ECG) is the most important diagn
MANAGEMENT• Initial therapy -> stabilizing patients condition, relieving ichemic pain,
antothrombotic therapy
• Pharmacologic anti-ischemic -> Nitrates, beta blockers• Pharmacologic antithrombotic -> Aspirin, clopidogrel, prasugrel, tica
glycoprotein
• Pharmacologic anticoagulant -> UFH, LMWH, Factor Xa inhibitors
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
24/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
25/44
SYMPTOMSMitral valve disease symptoms vary depending on the exact problem witA problem with your mitral valve may cause no symptoms at all. When syoccur, the can include:
• Cough
• Shortness of breath (especially when you are lying down on your back• Fatigue and tiredness
• Lightheadedness
DIAGNOSIS• Imaging test -> endocardiogram, x-ray, cardiac catheterization, etc
• Test of monitor heart activity -> electrocardiogram• Stress test
MANAGEMENT• Drugs and medications
• Valvuloplasty
• Surgery
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
26/44
B. AORTIC VALVE DISEASE
DEFINITION
Aortic valve disease is a condition in which the valve between the ma
chamber of your heart (left ventricle) and the main artery to your bodywork properly.
ETIOLOGY:
Congenital, rheumatic and senile calcific valve disease
Aortic Regurgitation (AR) imposes an acute or chronic volume load subsequent eccentric hypertrophy, LV enlargement, and eventual LV
DIAGNOSIS:• Hystory heart murmur, exertional or resting dyspnea, or symptoms
such as orthopnea, paroxysmal nocturnal dyspnea, or peripheral ed
• Auscultatory findings harsh systolic crescendo-decrescendo murmdiminished or absent aortic component of the second heart sound.
TREATMENT:
Surgery
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
27/44
C. PROSTHETIC HEART VALVES
DEFINITION
Bioprosthetic valves used in heart valve replacement generally offer functional prhemodynamics, resistance to thrombosis) that are more similar to those of nImplantation of prosthetic cardiac valves to treat hemodynamically significant aovalve disease has become increasingly common.
CLASSIFICATION:
Mechanical caged-ball (Starr-Edwards) valve, the single tilting-Shiley) valve, and bileaflet tilting-disk valves.
Bioprosthetic Heterografts, Homografts.
THERAPY:
Anticoagulant (tipically with warfarin) to prevent thromboembolism
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
28/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
29/44
ORAL HEALTH CONSIDERATION
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
30/44
5 Heart failures
• Inability of the cardiovascularsystem to meet the demandsof the end-programs
• May be due to pericardialdisease, valvular heart
disease, most commonly ->myocardial disease ->Systolic and Diastolicdysfunction
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
31/44
SIGN AND SYMPTOMS
• Exertional dyspnea and/or dyspnea at rest• Orthopnea• Acute pulmonary edema• Chest pain/pressure and palpitations• Tachycardia• Fatigue and weakness• Nocturia and oliguria• Anorexia, weight loss, nausea, etc
DIAGNOSIS
The following tests may be useful in the initial evaluation for suspected heart failure• Electrocardiography• Complete blood count (CBC)• Urinalysis• Electrolyte levels• Renal and liver function studies• Fasting blood glucose levels• Lipid profile
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
32/44
MANAGEMENT
• Nonpharmacologic therapy: Oxygen and noninvasive positventilation, dietary sodium and fluid restriction, physical activ
appropriate, and attention to weight gain• Pharmacotherapy: Diuretics, vasodilators, inotropic agents,
anticoagulants, beta blockers, and digoxin• Surgical options
ORAL HEALTH CONSIDERATIONS
• No special dental modifications for this patient• But, when patient suffer from uncompensated CHF, it is prudent to inquire abou
to be placed in a suspine positions
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
33/44
6 arrythmia• Is abnormalities of the heartbeat or cardiac rythms
• Caused by Primary cardiovascular disease, Pulmonary disorders, Autodisorders, Systemic diseases, Drug-related adverse effects, Electrolyteimbalances.
• Symptoms :
Fatigue Dizziness Lightheadedness
Fainting or near-fainting spells Rapid heartbeat or pounding
Shortness of breath Chest pain In extreme cases, collapse and sudden cardiac arrest
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
34/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
35/44
TREATMENT
• Bracycardias -> Pacemaker • Tachycardias -> Vagal maneuvers, Medications, Cardioversions, Cat
Ablations• Implantable devices : Pacemaker, ICD
• Surgery
ORAL HEALTH CONSIDERATIONS• Patients with supraventicular tachycardia -> Should be only treated b
consultation by cardiologist
• Patients with defibrilations and pacemaker -> no oral prophylaxys unpatients presents with an acute odontogenic infections
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
36/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
37/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
38/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
39/44
6
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
40/44
6 ENDOCARDITIS
Infection of the endocardial surface ofthe heart (see the image below), whichmay include one or more heart valves,the mural endocardium, or a septaldefect. Its intracardiac effects includesevere valvular insufficiency, which may
lead to intractable congestive heartfailure and myocardial abscesses. If leftuntreated, IE is generally fatal.
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
41/44
ETIOLOGY
Approximately 70% of infections in Endocarditis are caused
by Streptococcus species, including S viridans, Streptococcus b
enterococci. Staphylococcusspecies cause 25% of cases and ge
demonstrate a more aggressive acute course (see the images
PREDISPOSING CONDITION: Mitral valve prolapse
Aortic valve disease Congenital heart disease Prosthetic valve Intravenous drug use No identifiable cause in 25-47%
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
42/44
MANAGEMENT
- Antibiotic -> Penicillin G, Gentamicin
DENTAL CONSIDERATION:
Antibiotic prophylaxis a very high risk of developing endocarditis:
• Prosthetic heart valves.
• Previous infectious endocarditis.
• Congenital heart disease, only in the following
• Heart transplant patients who develop cardiac valve disease.
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
43/44
-
8/18/2019 Ppt Materi Om 2 Cardiovascular Disease
44/44